MX2021012428A - Metodo para el tratamiento de distrofia muscular de duchenne mediada por mutacion sin sentido en pacientes pediatricos. - Google Patents
Metodo para el tratamiento de distrofia muscular de duchenne mediada por mutacion sin sentido en pacientes pediatricos.Info
- Publication number
- MX2021012428A MX2021012428A MX2021012428A MX2021012428A MX2021012428A MX 2021012428 A MX2021012428 A MX 2021012428A MX 2021012428 A MX2021012428 A MX 2021012428A MX 2021012428 A MX2021012428 A MX 2021012428A MX 2021012428 A MX2021012428 A MX 2021012428A
- Authority
- MX
- Mexico
- Prior art keywords
- muscular dystrophy
- treating
- duchenne muscular
- nonsense mutation
- pediatric patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
En el presente documento se provee un método para mejorar o tratar la distrofia muscular de Duchenne mediada por mutación sin sentido (nmDMD) en un paciente pediátrico que lo necesita, que comprende administrar una cantidad eficaz de ataluren al paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962831931P | 2019-04-10 | 2019-04-10 | |
PCT/US2020/027382 WO2020210432A1 (en) | 2019-04-10 | 2020-04-09 | Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012428A true MX2021012428A (es) | 2022-01-19 |
Family
ID=72751530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012428A MX2021012428A (es) | 2019-04-10 | 2020-04-09 | Metodo para el tratamiento de distrofia muscular de duchenne mediada por mutacion sin sentido en pacientes pediatricos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220175739A1 (es) |
EP (1) | EP3952867A4 (es) |
JP (1) | JP2022526643A (es) |
KR (1) | KR20210151131A (es) |
CN (1) | CN114007608A (es) |
CA (1) | CA3135641A1 (es) |
EA (1) | EA202192767A1 (es) |
IL (1) | IL287053A (es) |
MX (1) | MX2021012428A (es) |
WO (1) | WO2020210432A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102665711B1 (ko) * | 2021-12-21 | 2024-05-14 | 재단법인 아산사회복지재단 | Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2203173T3 (en) * | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Materials and methods for prevention of muscle diseases |
PL3041958T4 (pl) * | 2013-09-04 | 2020-11-02 | Cold Spring Harbor Laboratory | Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi |
EP4085920A1 (en) * | 2016-01-06 | 2022-11-09 | Stealth BioTherapeutics Inc. | Methods for the treatment of duchenne muscular dystrophy |
-
2020
- 2020-04-09 US US17/602,576 patent/US20220175739A1/en active Pending
- 2020-04-09 WO PCT/US2020/027382 patent/WO2020210432A1/en unknown
- 2020-04-09 CN CN202080042488.8A patent/CN114007608A/zh active Pending
- 2020-04-09 KR KR1020217035972A patent/KR20210151131A/ko unknown
- 2020-04-09 MX MX2021012428A patent/MX2021012428A/es unknown
- 2020-04-09 EP EP20788548.4A patent/EP3952867A4/en active Pending
- 2020-04-09 EA EA202192767A patent/EA202192767A1/ru unknown
- 2020-04-09 JP JP2021559779A patent/JP2022526643A/ja active Pending
- 2020-04-09 CA CA3135641A patent/CA3135641A1/en active Pending
-
2021
- 2021-10-06 IL IL287053A patent/IL287053A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020210432A1 (en) | 2020-10-15 |
WO2020210432A8 (en) | 2021-10-28 |
EA202192767A1 (ru) | 2021-12-29 |
JP2022526643A (ja) | 2022-05-25 |
US20220175739A1 (en) | 2022-06-09 |
EP3952867A1 (en) | 2022-02-16 |
CA3135641A1 (en) | 2020-10-15 |
KR20210151131A (ko) | 2021-12-13 |
EP3952867A4 (en) | 2023-01-11 |
IL287053A (en) | 2021-12-01 |
CN114007608A (zh) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
NZ631289A (en) | Improved compositions for treating muscular dystrophy | |
MX2011009757A (es) | Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico. | |
EA201491460A1 (ru) | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα | |
EP4289475A3 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
MX2021012428A (es) | Metodo para el tratamiento de distrofia muscular de duchenne mediada por mutacion sin sentido en pacientes pediatricos. | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
MX2021004207A (es) | Uso de reboxetina para el tratamiento de narcolepsia. | |
ZA202007682B (en) | Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy | |
MX2019012088A (es) | Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias. | |
MX349767B (es) | Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. | |
NZ608133A (en) | Method and device for treating blood cholesterol disorders | |
PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
UA107928C2 (en) | Method of senility treatment | |
CR20220247A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
Gao | Pancolitis: 2 case reports | |
Whitehead | Dihydroergotamine mesilate | |
Marques et al. | Effect Of Positional Therapy On The Pharyngeal Structure Causing Collapse In Obstructive Sleep Apnea Patients | |
Ikeda | Alendronic acid/minodronic acid/zoledronic acid | |
UA129745U (uk) | Спосіб лікування хворих на бронхіальну астму з ішемічною хворобою серця |